Trials / Conditions / T-Cell Non-Hodgkin Lymphoma

T-Cell Non-Hodgkin Lymphoma

26 registered clinical trials studyying T-Cell Non-Hodgkin Lymphoma — 5 currently recruiting.

Status	Trial	Sponsor	Phase
Not Yet Recruiting	CD45BE-HSPC + CART-45 Cells NCT07451054	University of Pennsylvania	Phase 1
Recruiting	CD5 CAR T-Cell Therapy for r/r T-cell Lymphomas NCT07022964	Beijing GoBroad Hospital	Phase 1 / Phase 2
Recruiting	CD7 CAR T-Cell Therapy for r/r T-cell Lymphomas NCT06925464	Beijing GoBroad Hospital	Phase 1 / Phase 2
Recruiting	CD5-deleted Chimeric Antigen Receptor Cells (Senza5 CART5) for T Cell Non-Hodgkin Lymphoma (NHL) NCT06420089	Vittoria Biotherapeutics	Phase 1
Active Not Recruiting	Dose-Escalation and Dose-Expansion Study to Evaluate the Safety and Tolerability of Anti-CD7 Allogeneic CAR T- NCT05377827	Washington University School of Medicine	Phase 1
Completed	MargheRITA (Remote Intelligence for Therapeutic Adherence) NCT05260203	Advice Pharma Group srl	N/A
Completed	Romidepsin and Parsaclisib for the Treatment of Relapsed or Refractory T-Cell Lymphomas NCT04774068	Walter Hanel	Phase 1
Unknown	Anti-CD7 CAR-Engineered T Cells for T Lymphoid Malignancies Malignancies NCT04823091	Union Hospital, Tongji Medical College, Huazhong University of Science and Technology	Phase 1
Unknown	Non-gene Edited Anti-CD7 CAR T Cells for Relapsed/Refractory T Cell Malignances NCT04934774	iCell Gene Therapeutics	Phase 1
Unknown	Anti-CD5 CAR T Cells for Relapsed/Refractory T Cell Malignancies NCT04594135	iCell Gene Therapeutics	Phase 1
Unknown	Safety and Efficacy of ThisCART7 in Patients With Refractory or Relapsed T Cell Malignancies NCT05127135	Fundamenta Therapeutics, Ltd.	Phase 1
Completed	A Study of Zilovertamab Vedotin (MK-2140) (VLS-101) in Participants With Hematologic Malignancies (MK-2140-001 NCT03833180	VelosBio Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)	Phase 1
Terminated	Phase I/II Study Evaluating AUTO4 in Patients With T Cell Receptor Beta Constant (TRBC)1 Positive T Cell Lymph NCT03590574	Autolus Limited	Phase 1 / Phase 2
Terminated	Fludarabine Phosphate, Cyclophosphamide, Total Body Irradiation, and Donor Stem Cell Transplant in Treating Pa NCT03333486	Roswell Park Cancer Institute	Phase 2
Completed	Study to Assess Safety, Tolerability, Pharmacokinetics and Antitumor Activity of AZD4573 in Relapsed/Refractor NCT03263637	AstraZeneca	Phase 1
Terminated	Management of Platelet Transfusion Therapy in Patients With Blood Cancer or Treatment-Induced Thrombocytopenia NCT03195010	Fred Hutchinson Cancer Center	Phase 2
Completed	Phase I/Ib Study of Nivolumab & Veliparib in Patients With Advanced Solid Tumors & Lymphoma NCT03061188	Northwestern University	Phase 1
Recruiting	Allogeneic Stem Cell Transplantation in Relapsed/Refractory T-, NK/T-cell Lymphomas NCT02859402	Keimyung University Dongsan Medical Center	Phase 2
Completed	CD8+ Memory T-Cells as Consolidative Therapy After Donor Non-myeloablative Hematopoietic Cell Transplant in Tr NCT02424968	Robert Lowsky	Phase 2
Completed	Lenalidomide and Ipilimumab After Stem Cell Transplant in Treating Patients With Hematologic or Lymphoid Malig NCT01919619	M.D. Anderson Cancer Center	Phase 2
Completed	A Phase 2 Multicenter Study of High Dose Chemotherapy With Autologous Stem Cell Transplant Followed by Mainten NCT01908777	Memorial Sloan Kettering Cancer Center	Phase 2
Terminated	CHOEP + High Dose Therapy + Auto SCT for T-Cell Lymphoma NCT01746173	Dana-Farber Cancer Institute	Phase 2
Completed	Bortezomib and Vorinostat as Maintenance Therapy After Autologous Stem Cell Transplant in Treating Patients Wi NCT00992446	Fred Hutchinson Cancer Center	Phase 2
Completed	Fludarabine, Bendamustine, and Rituximab in Treating Participants With Lymphoid Cancers Undergoing Stem Cell T NCT00880815	M.D. Anderson Cancer Center	Phase 1
Completed	Donor Umbilical Cord Blood Transplant in Treating Patients With Hematologic Cancer NCT00723099	Fred Hutchinson Cancer Center	Phase 2
Completed	Gleevec in Relapsed/Refractory T Cell Non-Hodgkin's Lymphoma NCT00684411	Dana-Farber Cancer Institute	Phase 2